Amgen Inc (AMGN)
267.00
+4.25
(+1.62%)
USD |
NASDAQ |
Apr 19, 12:25
Amgen Enterprise Value: 194.48B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 194.48B |
| April 17, 2024 | 195.19B |
| April 16, 2024 | 196.03B |
| April 15, 2024 | 195.96B |
| April 12, 2024 | 196.91B |
| April 11, 2024 | 198.37B |
| April 10, 2024 | 196.46B |
| April 09, 2024 | 198.56B |
| April 08, 2024 | 197.94B |
| April 05, 2024 | 198.34B |
| April 04, 2024 | 197.34B |
| April 03, 2024 | 200.74B |
| April 02, 2024 | 201.70B |
| April 01, 2024 | 205.36B |
| March 28, 2024 | 206.04B |
| March 27, 2024 | 207.10B |
| March 26, 2024 | 204.67B |
| March 25, 2024 | 204.17B |
| March 22, 2024 | 201.67B |
| March 21, 2024 | 202.09B |
| March 20, 2024 | 200.00B |
| March 19, 2024 | 199.29B |
| March 18, 2024 | 198.85B |
| March 15, 2024 | 197.76B |
| March 14, 2024 | 199.19B |
| Date | Value |
|---|---|
| March 13, 2024 | 201.58B |
| March 12, 2024 | 201.87B |
| March 11, 2024 | 201.24B |
| March 08, 2024 | 200.38B |
| March 07, 2024 | 199.90B |
| March 06, 2024 | 201.90B |
| March 05, 2024 | 201.93B |
| March 04, 2024 | 203.40B |
| March 01, 2024 | 203.90B |
| February 29, 2024 | 200.42B |
| February 28, 2024 | 202.37B |
| February 27, 2024 | 202.92B |
| February 26, 2024 | 207.14B |
| February 23, 2024 | 208.65B |
| February 22, 2024 | 206.50B |
| February 21, 2024 | 205.58B |
| February 20, 2024 | 205.61B |
| February 16, 2024 | 205.71B |
| February 15, 2024 | 208.59B |
| February 14, 2024 | 209.12B |
| February 13, 2024 | 209.34B |
| February 12, 2024 | 211.46B |
| February 09, 2024 | 209.69B |
| February 08, 2024 | 211.53B |
| February 07, 2024 | 212.08B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
108.40B
Minimum
May 31 2019
227.44B
Maximum
Feb 01 2024
157.45B
Average
158.13B
Median
Enterprise Value Benchmarks
| Gilead Sciences Inc | 100.06B |
| Johnson & Johnson | 357.61B |
| Eli Lilly and Co | 731.61B |
| Merck & Co Inc | 345.18B |
| Vertex Pharmaceuticals Inc | 90.42B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 767.00M |
| Revenue (Quarterly) | 8.196B |
| Total Expenses (Quarterly) | 6.925B |
| EPS Diluted (Quarterly) | 1.42 |
| Gross Profit Margin (Quarterly) | 62.03% |
| Profit Margin (Quarterly) | 9.36% |
| Earnings Yield | 4.68% |
| Operating Earnings Yield | 5.50% |
| Normalized Earnings Yield | 4.678 |